Health Canada approves Ryaltris for treatment of Seasonal Allergic Rhinitis

Health Canada has approved Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) by Bausch Health and Glenmark for the symptomatic treatment of moderate-to-severe Seasonal Allergic Rhinitis (SAR) and associated ocular symptoms in adults, adolescents and children aged six years and older, the companies said in a joint statement.

Ryaltris is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray. The onset of action for nasal symptom relief occurs within 15 minutes after administration of Ryaltris, said the statement.